Hours

Minutes

Seconds

-40%

on all subscriptions*

Exceptional extension!

Enjoy this offer

* See conditions under "Our services"

Aptocrom Inc, formerly AP Healthcare Inc, is a Korea-based company primarily engaged in the pharmaceutical business. The Company operates its business through three segments. The Pharmaceutical Business segment is mainly engaged in the distribution and sale of drugs such as digestive organs medicine, outer skin medicine, nutrient tonic alteration and antibiotics. The Insulation Business segment is mainly engaged in the production, design, manufacturing and construction of industrial insulation. The Rental Business segment is mainly engaged in the real estate business such as offices and laboratories. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
19/06/26	1,810.00 ₩	-1.58%	8,437
18/06/26	1,839.00 ₩	+0.05%	5,130
17/06/26	1,838.00 ₩	-0.38%	10,430
16/06/26	1,845.00 ₩	-1.70%	23,329
15/06/26	1,877.00 ₩	+2.07%	7,353

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 19/06/2026			5-day change	1st Jan Change
1,810.00 ^KRW	-1.58%		-1.58%	-63.80%

05-26	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-14	APTOCROM Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	19.76B 12.91M 11.25M 10.42M 9.76M 18.3M 1.22B 18.41M 124M 47.92M 599M 48.45M 47.41M 2.08B	P/E 2024	-2.12x	P/E 2025	-9.5x
Enterprise Value	2.57B 1.68M 1.46M 1.35M 1.27M 2.38M 158M 2.39M 16.05M 6.22M 77.83M 6.29M 6.16M 270M	EV / Sales 2024	4.85x	EV / Sales 2025	3.87x
Free-Float	41.27%	Yield 2024 *	-	Yield 2025	-

05-26	Aprogen Biologics Inc. announced that it expects to receive KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-14	APTOCROM Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-08	Aprogen Medicines Inc. announced that it has received KRW 12 billion in funding from APTOCROM Inc.	CI
05-07	APTOCROM Inc. announced that it has received KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
04-28	Aprogen Medicines Inc. announced that it expects to receive KRW 12 billion in funding from APTOCROM Inc.	CI
04-28	APTOCROM Inc. announced that it expects to receive KRW 12.00000164 billion in funding from Nexkonics Inc.	CI
03-20	APTOCROM Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-16	APTOCROM Inc. announces Annual dividend	CI
11-13	APTOCROM Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
13/08/25	APTOCROM Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25/06/25	AP Healthcare Inc. announced that it has received KRW 10 billion in funding from Aprogen, Inc.	CI
22/05/25	Aprogen Medicines Inc. agreed to acquire an additional 20.06% stake in AP Healthcare Inc. from Aprogen Biologics Inc. for KRW 58.4 billion.	CI
14/05/25	APTOCROM Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

1 day	-1.58%
1 week	-1.58%
Current month	-40.85%
1 month	-40.85%
3 months	-47.99%
6 months	-66.85%
Current year	-63.80%

APTOCROM Inc. Stock

Stocks

A109960

KR7109960005

Pharmaceuticals

Valuation: APTOCROM Inc.

Chart: APTOCROM Inc.

Latest news : APTOCROM Inc.

Quotes and Performance

Course Extremes

Managers and Directors: APTOCROM Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,775	1,928
1 month	1,700	2,950
Current year	1,700	5,400
1 year	1,700	11,820
3 years	1,700	49,900
5 years	1,700	113,000
10 years	1,700	426,000

Manager	Title	Age	Since
Jung-Chool Kim CEO	Chief Executive Officer	70	23/03/2022
Jong-Su Kang SAM	Sales & Marketing	62	-
Young-Suk Yeom AUD	Comptroller/Controller/Auditor	51	-

Director	Title	Age	Since
Jae-Seob Kim BRD	Director/Board Member	63	10/01/2017
Jung-Chool Kim BRD	Director/Board Member	70	23/03/2022
Soon-Kyu Park BRD	Director/Board Member	59	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOCROM INC.	-1.58%	-1.58%	-73.30%	-93.91%	13.05M
ELI LILLY AND COMPANY	+0.16%	-2.75%	+42.51%	+139.96%	980B
JOHNSON & JOHNSON	+0.58%	-2.69%	+51.55%	+38.46%	550B
ABBVIE INC.	+4.70%	+2.24%	+23.29%	+64.88%	382B
ROCHE HOLDING AG	-0.27%	-3.09%	+23.33%	+16.78%	316B
ASTRAZENECA PLC	+0.26%	+0.26%	+27.01%	+14.09%	272B
NOVARTIS AG	+1.17%	-0.83%	+25.39%	+32.38%	268B
NOVO NORDISK A/S	+1.23%	+3.50%	-34.41%	-45.56%	199B
AMGEN INC.	+1.32%	-2.24%	+25.78%	+49.21%	182B
GILEAD SCIENCES, INC.	+0.34%	-0.32%	+16.68%	+58.62%	154B
Average	+0.80%	-2.79%	+12.78%	+27.49%	330.23B
Weighted average by Cap.	+0.94%	-3.50%	+30.53%	+63.52%

	2024	2025
Net sales	16.4B 10.71M 9.34M 8.65M 8.1M 15.19M 1.01B 15.28M 103M 39.77M 498M 40.21M 39.35M 1.73B	9.81B 6.41M 5.59M 5.17M 4.84M 9.08M 605M 9.14M 61.37M 23.79M 298M 24.05M 23.53M 1.03B
Net income	-28.09B -18.35M -16M -14.82M -13.87M -26.02M -1.73B -26.18M -176M -68.14M -852M -68.89M -67.41M -2.96B	-5.56B -3.63M -3.17M -2.93M -2.75M -5.15M -343M -5.18M -34.79M -13.48M -169M -13.63M -13.34M -586M
Net Debt	-25.07B -16.37M -14.28M -13.22M -12.38M -23.22M -1.55B -23.36M -157M -60.8M -761M -61.47M -60.15M -2.64B	-17.19B -11.23M -9.79M -9.07M -8.49M -15.92M -1.06B -16.02M -108M -41.7M -522M -42.16M -41.25M -1.81B